Skip to main content
International Journal of Environmental Research and Public Health logoLink to International Journal of Environmental Research and Public Health
. 2021 Dec 28;19(1):309. doi: 10.3390/ijerph19010309

Epidemiological Study of Return to Work and Mortality in Lung Cancer Survivors

Zhe-Yu Yang 1, Ching-Huang Lai 2, Ching-Liang Ho 3, Chung-Ching Wang 1,4,*
Editors: Oliver Faust, U Rajendra Acharya, Paul B Tchounwou
PMCID: PMC8744858  PMID: 35010569

Abstract

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide. Return to work (RTW) plays an important role for lung cancer survivors. Few studies focus solely on the relationship among possible variables and the RTW of lung cancer patients. The aim of our study was to examine sociodemographic, disease-related and work-related factors associated with RTW among lung cancer survivors in Taiwan. A total of 2206 employees who had been diagnosed with lung cancer at the Labor Insurance Database (LID), Taiwan Cancer Registry (TCR) and the National Health Insurance Research Database (NHIRD) during the period 2004–2015, were included in the study. We used the Cox proportional hazards model to investigate the associations between sociodemographic, disease-related and work-related factors on one hand and RTW on the other hand. The Kaplan–Meier method was used for analyzing the survival probability. Patients with an early cancer stage and those who underwent surgery had a higher likelihood of RTW. Factors including older age, male, higher monthly income and receipt of radiotherapy were inversely correlated with RTW. For lung cancer patients, RTW was a predictor of a lower risk of all-cause mortality in both the unadjusted and fully adjusted model. A better survival rate was found in stage III and IV lung cancer patients who had RTW. Sociodemographic and clinical-related variables had an impact on RTW among employees with lung cancer. RTW was correlated with a lower risk of all-cause mortality and better lung cancer survival. Our study showed the influence of RTW and independent confounding factors in lung cancer survivorship.

Keywords: lung cancer, return to work, survival outcome

1. Introduction

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in both sexes worldwide [1]. A total of 235,760 estimated new cases of lung cancer and 131,880 deaths from lung cancer were reported in the US in 2021 [2]. Lung cancer accounted for 19% of cancer deaths in Taiwan in 2017. Lung cancer mortality rates are high and overall 5-year survival rates are 21% [2]. Tobacco smoking, occupational exposures, air pollution and genetic predisposition are risk factors of lung cancer [3]. In Asia, exposure to indoor air pollution from cooking plays a crucial role in female lung cancer [4]. Traditional treatments for lung cancer included surgery, chemotherapy and radiotherapy [5]. In the past two decades, targeted therapies have been developed and approved as first-line therapies in lung cancer [6]. Immunotherapy had also been developed as a possible treatment option [7].

Mortality rates from lung cancer have been dropping due to lung cancer screening and novel treatment strategies [8,9]. However, lung cancer survivors still face many issues, including physical disability, psychological distress and social relationship problems [10,11]. Patients experienced pain, fatigue, weakness, shortness of breath and exercise intolerance [12]. Depression and anxiety were also present in patients with lung cancer [13,14]. The cost of cancer treatment and the loss of employment after a lung cancer diagnosis might cause economic problems [15]. Emerging studies have discussed the high financial burden that cancer patients face [16,17]. Moreover, a prior study reported that the unemployment rates of patients with lung cancer were two-fold higher than that of the general population [18]. Thus, the impact of lung cancer on RTW is worthy of attention.

Previous studies have investigated the correlation between the RTW of lung cancer survivors and variable factors [19,20]. However, prior research included limited samples of lung cancer survivors (<500 subjects). A paucity of studies investigated the relationship between RTW and survival rate for lung cancer patients. The objective of our retrospective cohort study was first, to explore the demographic, clinical and occupational variables correlated with RTW and second, to examine the association between RTW and survival rate among lung cancer survivors in Taiwan.

2. Materials and Methods

2.1. Study Population and Database

During the period 2004–2015, 2206 employees were newly diagnosed with lung cancer (ICD-O-3); information on these employees was collected from the Taiwan National Cancer Registry (TNCR) and the Taiwan Labor Insurance Database (LID) for this retrospective cohort study. Detailed descriptions are summarized in Figure 1. According to the International Classification of Diseases for Oncology—3rd edition (ICD-O-3), a primary diagnosis of lung cancer is coded. We utilized the unique encryption identity number to link these 2 databases in order to obtain sociodemographic information, such as age, employment information, employee’s industry, monthly income and company size. Disease-related information, including primary cancer site, cancer stage and types of treatment, were also collected. The exclusion criteria of our study were (1) death before enrolled period; (2) patients who had lung cancer combined with other cancer or unknown timing of lung cancer diagnosis; (3) lung cancer patient who was unemployed at baseline; (4) lung cancer diagnosis after 2010. The study protocol was reviewed by the Institutional Review Board (IRB) of Tri-Service General Hospital (TSGH) (IRB No. 1-107-05-129).

Figure 1.

Figure 1

Flow chart of study population.

2.2. Sociodemographic and Disease-Related Information

Sociodemographic data from the LID included age, monthly income, employment data, employee’s industry and company size. In accordance with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, clinical comorbidities were identified from National Health Insurance Research Database (NHIRD), including disorders of lipid metabolism, alcohol abuse, cerebrovascular diseases, chronic pulmonary diseases, peptic ulcer diseases, renal diseases, liver diseases and depression. Supplemental Table S1 lists the ICD-9-CM codes for clinical comorbidities. We also collected disease-related data, such as types of treatment and the pathological stage of lung cancer from TNCR and NHIRD.

2.3. Outcome Assessment

RTW was defined as employees who have still-insured labor insurance or first time re-insured labor insurance within 1 year of their lung cancer diagnosis. Non-RTW was defined as employees who exited labor insurance within 1 year of their lung cancer diagnosis and did not re-insure again. We selected an RTW period of 1–5 years after their first lung cancer diagnosis. We identified the information regarding RTW from employment data within LID. Every eligible participant was traced from their first-time primary diagnosis of lung cancer to the date of their death or the end of their follow-ups. We set the all-cause mortality (death from all causes) within the period 2004–2015 as the study endpoint.

2.4. Statistical Analysis

PROC PHREG of the SAS statistical package (version 9.4, SAS Institute Inc., Cary, NC, USA) was utilized to perform our data analyses. Two-sided p values < 0.05 were considered to be statistically significant. RTW was determined from the data of their first primary diagnosis of lung cancer to the reemployment date within five years. Survival time was calculated from the data of their first primary diagnosis of lung cancer to the date of their death during the follow-up period (2004–2015). The results of statistical analyses are described as the means, standard deviations (SD) and percentages. Differences of categorical variables between subgroups were analyzed by using a chi-squared test. Continuous variables were compared by using an independent t-test.

Cox regression is a technique for evaluating the association between variables and specific events [21]. We used a multivariable Cox proportional hazard regression as a statistical model to assess (1) the impact of confounding factors on RTW and (2) the relationship between all-cause mortality and RTW among lung cancer patients. Covariates including age, gender, pathological stage of lung cancer, received treatment, monthly income, employee’s industry and company size were adjusted. The HR (hazard ratio) represented the chance of RTW. Lastly, we used the Kaplan–Meier method to analyze the survival probability [22] and log-rank test to differentiate the survival curves between RTW and non-RTW groups.

3. Results

3.1. Characteristics of the Study Population

The sociodemographic characteristics of the study population are shown in Table 1. The mean age of the participants was 53.5 ± 8.2 years. Of the 2206 patients, 1095 (49.6%) workers were male and 1109 (50.2%) workers had a monthly income range below USD 960. In this study, the early stage (stage 0 and I) of lung cancer were in the majority (48.4%), followed by stage IV (20.3%), stage III (19.6%) and stage II (11.6%). A total of 1805 (81.8%) employees received surgical intervention, while less than half of the workers received chemotherapy (39.4%) or radiotherapy (15.5%). The employment rates of lung cancer survivors 2 and 5 years after their RTW were 60.3% and 41.1%, respectively.

Table 1.

Characteristics of the study population.

Characteristic Total RTW Group Non-RTW Group
Number of Patient % 2-Year RTW
n = 1332
5-Year RTW
n = 908
p Value 2-Year RTW
n = 874
5-Year RTW
n = 1298
p Value
Age(year) a 53.5 ± 8.2 (26–91) - 52.8 ± 8 (26–81) 52.3 ± 8 (26–81) 54.6 ± 8.4 (26–91) 54.4 ± 8.2 (26–91)
Gender
Male 1095 49.63 553 346 0.1059 542 749 0.0449
Comorbidities
Lipoid metabolism 289 13.1 188 120 0.5445 101 169 0.3106
Alcohol abuse 20 0.9 10 6 0.804 10 14 0.886
Hypertension 501 22.71 289 191 0.708 212 310 0.8417
Congestive heart failure 34 1.54 22 10 0.2812 12 24 0.3942
Peripheral vascular disease 23 1.04 12 10 0.6368 11 13 0.5741
Cerebrovascular disease 60 2.71 30 18 0.665 30 42 0.8017
Chronic pulmonary disease 396 17.95 215 144 0.8582 181 252 0.4589
Rheumatologic disease 36 1.63 28 22 0.6138 8 14 0.7094
Peptic ulcer disease 240 10.87 139 104 0.4467 101 136 0.4292
Mild liver disease 206 9.33 117 78 0.8733 89 128 0.8063
Renal disease 32 1.45 24 12 0.3749 8 20 0.2051
Depression 65 2.94 36 22 0.6823 29 43 0.9946
Comorbidity
0 1097 49.72 676
1 578 26.2 348
2 322 14.59 189
≥3 209 9.47 119
Treatment
OP 1805 81.82 1211 859 0.0012 594 946 0.0133
RTB 343 15.54 141 62 0.0024 202 281 0.4212
CH 870 39.43 477 272 0.0039 393 598 0.6121
Monthly income (USD) 0.1728 0.312
≤$960 1109 50.27 715 519 394 590
>$960–$1273 395 17.9 270 182 125 213
>$1273 702 31.82 347 207 355 495
Employee’s industry 0.9589 0.9977
Agriculture 154 6.98 97 69 57 85
Manufacturing 692 31.36 415 290 277 402
Electricity and Gas Supply 14 0.63 8 4 6 10
Water Supply 13 0.58 7 5 6 8
Construction 232 10.51 129 95 103 137
Wholesale and Retail Trade 254 11.51 152 90 102 164
Transportation and Storage 168 7.61 99 54 69 114
Food Service 74 3.35 46 30 28 44
Information 30 1.35 22 14 8 16
Financial 82 3.71 50 36 32 46
Real Estate Activities 29 1.31 18 6 11 23
Technical Activities 63 2.85 32 23 31 40
Support Service Activities 63 2.85 38 29 25 34
Public Administration 40 1.81 18 15 22 25
Education 36 1.63 21 14 15 22
Human Health 67 3.03 47 40 20 27
Arts 28 1.26 18 10 10 18
Other Service Activities 167 7.57 115 84 52 83
Company size b 0.8169 0.6518
Company closed 187 8.47 104 62 83 125
Small 167 7.57 90 65 77 102
Medium 260 183 200 277
Large 878 598 514 794
Pathological stage <0.0001 0.0586
0 & I 1068 48.41 776 611 292 457
II 257 11.65 168 116 89 141
III 433 19.62 252 126 181 307
IV 448 20.3 136 55 312 393

Abbreviation: RTW = return to work, OP = operation, RTB = radiotherapy, CH = chemotherapy. a values are mean (standard deviation). b Company size: small (less than 5 people), medium (less than 200 people in manufacturing, construction, mining and quarrying; or less than 100 people in other industries), large (more than 200 people in manufacturing, construction, mining and quarrying; or more than 100 people in other industries).

3.2. Univariate Analysis of Independent Factors Associated with RTW in Cox Proportional Hazards Models

Figure 2 shows the independent factors associated with RTW using univariate Cox proportional hazards models. A lower likelihood of RTW was associated with older age, male and a monthly income above USD 1273. The patients who received chemotherapy or radiotherapy were less likely to RTW. These two HRs gradually declined during the follow-up period (chemotherapy: second year HR = 0.84; 95% CI = 0.75–0.94 to fifth year HR = 0.64; 95% CI = 0.55–0.73; radiotherapy: second year HR = 0.63; 95% CI = 0.52–0.75 to fifth year HR = 0.39; 95% CI = 0.3–0.51). A greater likelihood of RTW was associated with early stage cancer and receiving surgery.

Figure 2.

Figure 2

Forest tree plot showing the HR obtained by univariate Cox proportional hazards model of return to work for lung cancer survivors in (A) 2-year RTW and (B) 5-year RTW.

3.3. Multivariate Analysis of Independent Factors Associated with RTW in Cox Proportional Hazards Models

An examination of the correlation of RTW and independent factors using multivariate Cox proportional hazards models suggested that the factors correlated with a lower likelihood of RTW were older age, male, a monthly income above USD 1273 and receiving radiotherapy (Figure 3). The patients who received surgery had a higher chance of RTW during the study period. Compared with the participants with stage IV, the participants with stage 0, I, II or III had a higher chance of RTW.

Figure 3.

Figure 3

Forest tree plot showing the HR obtained by multivariate Cox proportional hazards model of return to work for lung cancer survivors in (A) 2-year RTW and (B) 5-year RTW.

3.4. Survival Rates by RTW and Non-RTW

The survival rates using the Kaplan–Meier curve stratified by RTW and non-RTW are listed in Figure 4. The patients who had RTW had a better survival probability than those who had not RTW in all the cases of lung cancer (p < 0.001) and especially for patients with stage III and IV (p < 0.01).

Figure 4.

Figure 4

Kaplan–Meier (KM) curves showed survival probability of RTW for (A) all, (B) stages 0 and 1 and (CE) stages 2–4 lung cancer survivors.

3.5. Multivariate Analysis of RTW and All-Cause Mortality in Cox Proportional Hazards Models

After using Cox proportional hazards models to adjust the confounding variables, the association of all-cause mortality between lung cancer survivors who had RTW and those who had not is shown in Table 2. An inverse relationship between all-cause mortality and RTW among lung cancer patients was observed in both the unadjusted and fully adjusted model (p < 0.001; p < 0.001).

Table 2.

Uni- and multivariate analysis of RTW and all-cause mortality in Cox proportional hazards models.

Unadjusted All-Cause Mortality p Adjusted All-Cause Mortality p
RTW 0.508 (0.447–0.578) <0.0001 0.508 (0.441–0.586) <0.0001

4. Discussion

Our study investigated the independent factors associated with RTW and examined the correlation between all-cause mortality and RTW among lung cancer patients in Taiwan. We found that employees with stages 0, I and II cancer had a higher likelihood of RTW, while factors correlated with a reduced likelihood of RTW were higher income and receiving radiotherapy. Lung cancer survivors who had RTW had lower all-cause mortality rates than those who had not. Moreover, through the Kaplan–Meier curve, the RTW group had better survival rates than the non-RTW group.

There have been many studies examining the association between RTW and cancer survivorship [23]. In a systemic review, Mehnert reported that 40% of patients had returned to work or had continued to work after 6 months of treatment, 62% by 12 months and 89% by 24 months [24]. However, the RTW rate of cancer patients was widely different depending on cancer type. A prospective study demonstrated that patients with breast cancer or skin cancer had a higher RTW rate. On the contrary, patients with lung cancer or head and neck cancer had a lower RTW rate [25]. Another study showed patients with skin or stomach cancer had higher employment rates compared to patients with lung or central nervous system cancer [26]. Earle and his colleagues reported only 21% of lung cancer survivors remained employed in the 15 months after their cancer diagnosis [27]. A recent cross-sectional study from Germany revealed a 33% employment rate within 1 year after being diagnosed with lung cancer [28]. Our study found a 41% employment rate in the fifth year of the follow-up period. The possible reasons for the relatively low RTW rate of lung cancer survivors have been addressed. A review article on the employment-related factors of cancer survivors suggested that the poor 5-year survival rates of lung cancer patients might cause the low likelihood of RTW [29]. Polanski et al. stated that lung cancer survivors had a lower quality of life compared to other cancer survivors [10].

Sociodemographic factors including age, education and income were examined to be associated with RTW [26]. A prospective study in the US indicated that a lower educational level and income were associated with unemployment [27]. Kim and his colleagues found that a low employment rate was correlated with older age and lower household income among lung cancer survivors [18]. However, our study revealed that a higher monthly income was correlated with a lower likelihood of RTW, which is inconsistent with previous studies. There are several explanations for these conflicting findings. The Taiwanese National Health Insurance system has provided comprehensive coverage, including the medical expense of cancer treatment [30]. The coverage rate of the Taiwanese National Health Insurance is nearly 99.9%, and around 93% of medical care institutions in Taiwan are contracted with the National Health Insurance system. Taken together, cancer patients in Taiwan face less financial stress on treatment costs. From an economic perspective, the higher monthly income group might have better financial reserves that allow them to take long-term sick leave.

In the present study, we found that lung cancer survivors who had RTW had higher survival rates and lower risk of all-cause mortality. An American review stated that RTW could help to improve recovery in many aspects, such as social, psychological and physical functioning [31]. Schmidt et al. discovered that participants who RTW have a better quality of life and cognitive performance than those who did not RTW [32]. A cross-sectional study from a single cancer center demonstrated that cancer survivors who remained in their jobs had fewer mental illnesses compared with those were out of work [33]. According to these findings, re-employment in cancer patients might indicate the recovery of physical function and improvement of cancer survival. Our results are in line with this inference.

There are several limitations in our study. First, there was a lack of information about other sociodemographic factors and psychosocial work-related factors, which may be possible confounding factors affecting the RTW. Second, we only recruited Taiwanese participants, which might limit the generalizability of our findings to different racial populations. Third, we did not take into account the side effects of treatment, such as fatigue, which was the most common work-related problem in lung cancer patients.

5. Conclusions

Our study showed RTW was correlated with a lower risk of all-cause mortality and better lung cancer survival. The findings might be explained by a stable income and better performance status accompanied by RTW. Our results demonstrated the impact of RTW and independent confounding factors in lung cancer survivorship. Accessing the side effects of treatment, quality of life, work accommodation and work discrimination may be considered in future studies.

Acknowledgments

We gratefully acknowledge the contribution of the late Saou-Hsing Liou and Ya-Yuan Hsu to this paper.

Supplementary Materials

The following are available online at www.mdpi.com/article/10.3390/ijerph19010309/s1, Table S1: The ICD-9-CM codes for clinical comorbidities.

Author Contributions

Z.-Y.Y. contributed to the design of the study, was responsible for data-analysis decisions, was responsible for the management and retrieval of data, decided on data-collection methods and initial data analysis and interpretation, contributed to initial data analysis and interpretation, and drafted the initial article. C.-H.L. and C.-L.H. decided on the data-collection methods and initial data analysis and interpretation. C.-C.W. conceptualized and designed the study, contributed to the design of the study, supervised all aspects of the study, was responsible for data-analysis decisions, decided on data-collection methods and initial data analysis and interpretation, was responsible for the management and retrieval of data, contributed to initial data analysis and interpretation, drafted the initial article, critically reviewed and revised the article, and approved the final version for submission. All authors meet the International Committee of Medical Journal Editors criteria for authorship. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Institute of Labor, Occupational Safety, and Health (ILOSH) and the Ministry of Labor (ILOSH107-M301) in Taiwan.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Tri-Service General Hospital (TSGH) (IRB No. 1-107-05-129).

Informed Consent Statement

Subject informed consent was waived in this study because our data were collected from the database of the Taiwan Cancer Registry (TCR), Labor Insurance Database (LID) and National Health Insurance Research Database (NHIRD). Those databases were provided under de-identification status. We can only link the data by a unique encryption identity number. All of the procedures were approved by the Institutional Review Board (IRB) of Tri-Service General Hospital, Taiwan (IRB No. 1-107-05-129).

Data Availability Statement

The data underlying this study are from the Labor Insurance Database (LID) and National Health Insurance Research Database (NHIRD). The LID and NHIRD is not free to public access, and therefore, interested researchers can obtain the data through formal application to the Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan. (https://dep.mohw.gov.tw/DOS/np-2497-113.html). Last accessed date: 29 June 2020.

Conflicts of Interest

The authors declared that they had no competing interests.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
  • 2.Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. [DOI] [PubMed] [Google Scholar]
  • 3.Malhotra J., Malvezzi M., Negri E., La Vecchia C., Boffetta P. Risk factors for lung cancer worldwide. Eur. Respir. J. 2016;48:889–902. doi: 10.1183/13993003.00359-2016. [DOI] [PubMed] [Google Scholar]
  • 4.Torre L.A., Siegel R.L., Jemal A. Lung Cancer Statistics. Adv. Exp. Med. Biol. 2016;893:1–19. doi: 10.1007/978-3-319-24223-1_1. [DOI] [PubMed] [Google Scholar]
  • 5.Latimer K.M., Mott T.F. Lung cancer: Diagnosis, treatment principles, and screening. Am. Fam. Physician. 2015;91:250–256. [PubMed] [Google Scholar]
  • 6.Chirieac L.R., Dacic S. Targeted Therapies in Lung Cancer. Surg. Pathol. Clin. 2010;3:71–82. doi: 10.1016/j.path.2010.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Corrales L., Scilla K., Caglevic C., Miller K., Oliveira J., Rolfo C. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. Adv. Exp. Med. Biol. 2018;995:65–95. doi: 10.1007/978-3-030-02505-2_3. [DOI] [PubMed] [Google Scholar]
  • 8.Jonas D.E., Reuland D.S., Reddy S.M., Nagle M., Clark S.D., Weber R.P., Enyioha C., Malo T.L., Brenner A.T., Armstrong C., et al. Screening for Lung Cancer with Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325:971–987. doi: 10.1001/jama.2021.0377. [DOI] [PubMed] [Google Scholar]
  • 9.Howlader N., Forjaz G., Mooradian M.J., Meza R., Kong C.Y., Cronin K.A., Mariotto A.B., Lowy D.R., Feuer E.J. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N. Engl. J. Med. 2020;383:640–649. doi: 10.1056/NEJMoa1916623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Polanski J., Jankowska-Polanska B., Rosinczuk J., Chabowski M., Szymanska-Chabowska A. Quality of life of patients with lung cancer. Onco. Targets Ther. 2016;9:1023–1028. doi: 10.2147/ott.s100685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Vijayvergia N., Shah P.C., Denlinger C.S. Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward. J. Natl. Compr. Cancer Netw. 2015;13:1151–1161. doi: 10.6004/jnccn.2015.0140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hechtner M., Eichler M., Wehler B., Buhl R., Sebastian M., Stratmann J., Schmidberger H., Gohrbandt B., Peuser J., Kortsik C., et al. Quality of Life in NSCLC Survivors—A Multicenter Cross-Sectional Study. J. Thorac. Oncol. 2019;14:420–435. doi: 10.1016/j.jtho.2018.11.019. [DOI] [PubMed] [Google Scholar]
  • 13.Khue P.M., Thom V.T., Minh D.Q., Quang L.M., Hoa N.L. Depression and Anxiety as Key Factors Associated with Quality of Life Among Lung Cancer Patients in Hai Phong, Vietnam. Front. Psychiatry. 2019:10. doi: 10.3389/fpsyt.2019.00352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Arrieta O., Angulo L.P., Nunez-Valencia C., Dorantes-Gallareta Y., Macedo E.O., Martinez-Lopez D., Alvarado S., Corona-Cruz J.F., Onate-Ocana L.F. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann. Surg. Oncol. 2013;20:1941–1948. doi: 10.1245/s10434-012-2793-5. [DOI] [PubMed] [Google Scholar]
  • 15.Nekhlyudov L., Walker R., Ziebell R., Rabin B., Nutt S., Chubak J. Cancer survivors’ experiences with insurance, finances, and employment: Results from a multisite study. J. Cancer Surviv. 2016;10:1104–1111. doi: 10.1007/s11764-016-0554-3. [DOI] [PubMed] [Google Scholar]
  • 16.Carrera P.M., Kantarjian H.M., Blinder V.S. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J. Clin. 2018;68:153–165. doi: 10.3322/caac.21443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zhang X., Liu S., Liu Y., Du J., Fu W., Zhao X., Huang W., Zhao X., Liu G., Mao Z., et al. Economic Burden for Lung Cancer Survivors in Urban China. Int. J. Environ. Res. Public Health. 2017;14:308. doi: 10.3390/ijerph14030308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kim Y.A., Yun Y.H., Chang Y.J., Lee J., Kim M.S., Lee H.S., Zo J.I., Kim J., Choi Y.S., Shim Y.M., et al. Employment status and work-related difficulties in lung cancer survivors compared with the general population. Ann. Surg. 2014;259:569–575. doi: 10.1097/SLA.0b013e318291db9d. [DOI] [PubMed] [Google Scholar]
  • 19.Torp S., Nielsen R.A., Fosså S.D., Gudbergsson S.B., Dahl A.A. Change in employment status of 5-year cancer survivors. Eur. J. Public Health. 2012;23:116–122. doi: 10.1093/eurpub/ckr192. [DOI] [PubMed] [Google Scholar]
  • 20.Sjövall K., Attner B., Englund M., Lithman T., Noreen D., Gunnars B., Thomé B., Olsson H., Petersson I.F. Sickness absence among cancer patients in the pre-diagnostic and the post-diagnostic phases of five common forms of cancer. Support. Care Cancer. 2012;20:741–747. doi: 10.1007/s00520-011-1142-8. [DOI] [PubMed] [Google Scholar]
  • 21.Bradburn M.J., Clark T.G., Love S.B., Altman D.G. Survival analysis part II: Multivariate data analysis--an introduction to concepts and methods. Br. J. Cancer. 2003;89:431–436. doi: 10.1038/sj.bjc.6601119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Goel M.K., Khanna P., Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int. J. Ayurveda Res. 2010;1:274–278. doi: 10.4103/0974-7788.76794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.van Muijen P., Weevers N.L., Snels I.A., Duijts S.F., Bruinvels D.J., Schellart A.J., van der Beek A.J. Predictors of return to work and employment in cancer survivors: A systematic review. Eur. J. Cancer Care. 2013;22:144–160. doi: 10.1111/ecc.12033. [DOI] [PubMed] [Google Scholar]
  • 24.Mehnert A. Employment and work-related issues in cancer survivors. Crit. Rev. Oncol. Hematol. 2011;77:109–130. doi: 10.1016/j.critrevonc.2010.01.004. [DOI] [PubMed] [Google Scholar]
  • 25.Mehnert A., Koch U. Predictors of employment among cancer survivors after medical rehabilitation—A prospective study. Scand. J. Work Environ. Health. 2013;39:76–87. doi: 10.5271/sjweh.3291. [DOI] [PubMed] [Google Scholar]
  • 26.Kiasuwa Mbengi R., Otter R., Mortelmans K., Arbyn M., Van Oyen H., Bouland C., de Brouwer C. Barriers and opportunities for return-to-work of cancer survivors: Time for action—Rapid review and expert consultation. Syst. Rev. 2016;5:35. doi: 10.1186/s13643-016-0210-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Earle C.C., Chretien Y., Morris C., Ayanian J.Z., Keating N.L., Polgreen L.A., Wallace R., Ganz P.A., Weeks J.C. Employment among survivors of lung cancer and colorectal cancer. J. Clin. Oncol. 2010;28:1700–1705. doi: 10.1200/JCO.2009.24.7411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Rashid H., Eichler M., Hechtner M., Gianicolo E., Wehler B., Buhl R., Schmidberger H., Stratmann J.A., Gohrbandt B., Kortsik C., et al. Returning to work in lung cancer survivors—A multi-center cross-sectional study in Germany. Support. Care Cancer. 2021;29:3753–3765. doi: 10.1007/s00520-020-05886-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Taskila T., Lindbohm M.L. Factors affecting cancer survivors’ employment and work ability. Acta. Oncol. 2007;46:446–451. doi: 10.1080/02841860701355048. [DOI] [PubMed] [Google Scholar]
  • 30.Hung M.-C., Lai W.-W., Chen H.H.W., Lee J.-C., Lin Y.-J., Hsiao J.-R., Cheng Y.-M., Shan Y.-S., Su W.-C., Wang J.-D. Cost effectiveness of cancer treatment in Taiwan. J. Formos. Med. Assoc. 2016;115:609–618. doi: 10.1016/j.jfma.2016.04.002. [DOI] [PubMed] [Google Scholar]
  • 31.Feuerstein M., Todd B.L., Moskowitz M.C., Bruns G.L., Stoler M.R., Nassif T., Yu X. Work in cancer survivors: A model for practice and research. J. Cancer Surviv. 2010;4:415–437. doi: 10.1007/s11764-010-0154-6. [DOI] [PubMed] [Google Scholar]
  • 32.Schmidt M.E., Scherer S., Wiskemann J., Steindorf K. Return to work after breast cancer: The role of treatment-related side effects and potential impact on quality of life. Eur. J. Cancer Care. 2019;28:e13051. doi: 10.1111/ecc.13051. [DOI] [PubMed] [Google Scholar]
  • 33.Kuroki L.M., Morris D.H., Greenwade M., Landon M., Hagemann A.R., Thaker P.H., Massad L.S., McCourt C.K., Fuh K.C., Powell M.A., et al. Impact of employment and insurance status on distress in gynecologic oncology patients. Gynecol. Oncol. 2021;161:477–482. doi: 10.1016/j.ygyno.2021.01.038. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The data underlying this study are from the Labor Insurance Database (LID) and National Health Insurance Research Database (NHIRD). The LID and NHIRD is not free to public access, and therefore, interested researchers can obtain the data through formal application to the Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan. (https://dep.mohw.gov.tw/DOS/np-2497-113.html). Last accessed date: 29 June 2020.


Articles from International Journal of Environmental Research and Public Health are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES